~
Ovarian cancer is the fifth leading cause of cancer death among American women. In 2014, it killed more than 14,000 women. Given the rate of diagnosis, there are more women in the pipeline for next year and the next and the one after that. If you are not fighting this disease, you probably know someone who is.
 
That’s yesterday’s news. Today’s news is that the Federal Drug Administration is willing to support continued research into a treatment option that is based on Dronabinol, a cannabinoid, which is one of the many non-THC derivatives of the cannabis plant. The prospects for the future include not only better treatment options for those diagnosed with ovarian cancer, but more research into the largely untouched medical potential of cannabis.
 
Ovarian Cancer
 
It is a hard disease to detect and treat. The symptoms of the early stages, when it is most curable, are subtle and many women dismiss them. It is resistant to current treatments, particularly after the first drug round. Much depends on the stage at which this kind of cancer is diagnosed, but the overall five-year survival rate is less than half.
 
So, message number one for all you ladies out there, especially if you are white and over 60, is to get yourselves into the doctor’s office for a checkup.
 
Treatment Options and Issues
 
When the diagnosis is ovarian cancer, doctors often recommend aggressive measures, including two or more different types of treatments. The options include surgery, chemotherapy, hormone therapy, targeted therapy and radiation therapy. Each can have life-threatening complications.
 
Insys Therapeutic Inc.’s Liposomal Encapsulated Paclitaxel, a drug which contains Dronabinol, may soon be part of the package of options. In drug trials it has reportedly been effective in the treatment of the nausea and vomiting associated with cancer chemotherapy as well as anorexia associated with weight loss in patients with AIDS.
 
What’s New?
 
Cannabis as medicine is not new; the recognition that it may be helpful in treating nausea is not new, but the investment incentives that come with FDA greenlighting are new. LEP’s special status under The Orphan Drug Act, qualifies Insys for various development incentives, including tax credits for qualified clinical testing and a seven-year period of U.S. marketing exclusivity upon approval. These incentives may support LEP’s development.
 
Broader Implications
 
Additional treatment options for patients undergoing chemotherapy or who are otherwise fighting weight loss are important. Development incentives for drug companies should expand those options. That is good for drug companies.
 
The larger investment picture, however, involves the recognition that cannabis and cannabis derivatives may have acceptable medical uses that are inconsistent with its classification as a Schedule I drug. Every recognized medical use helps to build a stronger case for descheduling. Were cannabis removed from the Controlled Substance Act’s schedules, research into other medical uses would be easier to fund. Investors would be more willing to support research. The virtuous circle of growth and investment could begin to function.
 
Anne Wallace ~ MJI News ~ January 29, 2015
 
~
November 15, 2019

Law Enforcement Prepares For Legal Cannabis in…

As Illinois prepares to legalize recreational marijuana, one group preparing for a cultural sea-change is the very group responsible for…
November 15, 2019

Holiday Gift Guide 2019: The Best Cannabis…

in Travel

While traveling with cannabis is still technically illegal -- even when you’re going to or coming from a legal state,…
November 15, 2019

Australia: Women with endometriosis are turning to…

For some women with endometriosis, surgery and medication just aren't cutting it to alleviate their pain and other symptoms. One…
November 15, 2019

Two-thirds of Americans support marijuana legalization -…

Two-thirds of Americans say the use of marijuana should be legal, reflecting a steady increase over the past decade, according…
November 14, 2019

Florida Medical Marijuana Use Doubles In Just…

Since this time last year, the number of medical marijuana patients in Florida has more than doubled.
November 14, 2019

Is tissue culture the future of growing…

Cannabis cultivators need a clean, reproducible growing process that can cater to high demand and create consistent product. Enter large-scale,…
November 14, 2019

Pennsylvania medical marijuana sales top $500 million…

Pennsylvania's medical marijuana program has generated more than $500 million in sales since it began operating two years ago, according…
November 14, 2019

Michigan recreational marijuana retail sales to begin…

Michigan residents will be able to legally purchase marijuana from stores beginning Dec. 1, the state Marijuana Regulatory Agency announced…
November 13, 2019

Israeli government throws its weight behind medical…

With the issuance of a wide-ranging ministry report on the medical cannabis industry, Israel is for the first time making…
November 13, 2019

Can Industrial Hemp Make Automobiles More Green?…

Unlike petrochemical-based lubricants, hemp is a renewable resource that actually reduces carbon dioxide in the air.
November 13, 2019

'I was in chronic pain. Medicinal cannabis…

Lara Smith is a former nurse in the UK who relies on medicinal cannabis for pain relief, but still can't…